Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort
Table 3
(a) Cox regression analyses by mammographic features in primary DCIS (). (b) Cox regression analyses by mammographic features in primary DCIS treated by breast conserving surgery ().
(a)
Ductal carcinoma in situ
Mammographic features
Stellate
Circular or oval shaped
Powdery calcifications
Crushed stone calcifications
Casting type calcifications
Galactographic finding
Architectural distortion
Normal mammography
Numbers at risk ()
16
47
29
192
89
15
28
16
IBEs (in situ or invasive)
Univariate HR (95% CI)
1.10 (0.40–3.05)
0.94 (0.47–1.86)
0.99 (0.47–2.10)
Reference
0.59 (0.32–1.07)
1.28 (0.51–3.21)
1.04 (0.47–2.30)
1.08 (0.39–3.00)
Adjusted HR (95% CI)
0.92 (0.33–2.55)
0.88 (0.44–1.74)
0.98 (0.46–2.07)
Reference
0.67 (0.37–1.22)
1.90 (0.75–4.81)
1.27 (0.57–2.82)
1.07 (0.38–2.97)
AIEs
Univariate HR (95% CI)
1.58 (0.48–5.21)
1.11 (0.49–2.53)
0.62 (0.19–2.03)
Reference
0.41 (0.17–0.99)
1.28 (0.39–4.19)
1.55 (0.64–3.74)
1.53 (0.47–5.01)
Adjusted HR (95% CI)
1.47 (0.45–4.87)
1.11 (0.48–2.55)
0.63 (0.19–2.08)
Reference
0.47 (0.20–1.15)
1.87 (0.56–6.23)
1.98 (0.81–4.83)
1.63 (0.49–5.36)
Adjusted for type of surgery and postoperative radiotherapy. BCS = breast conserving surgery; IBE = ipsilateral breast event; AIE = IBE, regional recurrence and generalized disease.
(b)
Ductal carcinoma in situ
Mammographic features
Stellate
Circular or oval shaped
Powdery calcifications
Crushed stone calcifications
Casting type calcifications
Galactographic finding
Architectural distortion
Normal mammography
Numbers at risk ()
14
40
25
159
64
9
18
12
IBEs (in situ or invasive)
Univariate HR (95% CI)
1.03 (0.37–2.87)
0.97 (0.49–1.92)
0.98 (0.46–2.07)
Reference
0.65 (0.35–1.20)
1.63 (0.58–4.52)
1.36 (0.58–3.19)
0.88 (0.27–2.82)
Adjusted HR (95% CI)
0.92 (0.33–2.56)
0.90 (0.45–1.78)
0.99 (0.47–2.10)
Reference
0.66 (0.36–1.22)
1.79 (0.64–4.98)
1.22 (0.52–2.86)
0.83 (0.26–2.67)
Invasive IBEs
Univariate HR (95% CI)
1.63 (0.49–5.43)
0.78 (0.27–2.25)
0.74 (0.22–2.45)
Reference
0.38 (0.13–1.08)
1.75 (0.41–7.42)
1.87 (0.65–5.43)
1.19 (0.28–5.03)
Adjusted HR (95% CI)
1.47 (0.44–4.93)
0.72 (0.25–2.09)
0.76 (0.23–2.52)
Reference
0.38 (0.13–1.09)
2.03 (0.48–8.69)
1.64 (0.56–4.78)
1.08 (0.25–4.59)
In situ IBEs
Univariate HR (95% CI)
0.55 (0.07–4.06)
1.15 (0.47–2.83)
1.29 (0.49–3.41)
Reference
0.90 (0.41–1.95)
1.78 (0.42–7.57)
0.97 (0.23–4.14)
0.61 (0.08–4.55)
Adjusted HR (95% CI)
0.49 (0.07–3.61)
1.02 (0.41–2.52)
1.28 (0.48–3.38)
Reference
0.91 (0.42–1.97)
1.93 (0.45–8.21)
0.84 (0.20–3.61)
0.54 (0.07–4.02)
AIEs
Univariate HR (95% CI)
1.66 (0.50–5.48)
1.29 (0.56–2.97)
0.67 (0.20–2.21)
Reference
0.44 (0.17–1.15)
2.38 (0.72–7.88)
2.16 (0.83–5.63)
1.24 (0.29–5.22)
Adjusted HR (95% CI)
1.57 (0.47–5.22)
1.22 (0.53–2.82)
0.67 (0.20–2.23)
Reference
0.45 (0.17–1.16)
2.49 (0.75–8.28)
2.05 (0.78–5.37)
1.21 (0.29–5.10)
Adjusted for postoperative radiotherapy. IBE = ipsilateral breast event; AIE = IBE, regional recurrence and generalized disease.
